急性冠脉综合征患者中替格瑞洛与普拉格雷的比较
该多中心、随机、开放标签试验纳入4018例计划行侵入性评估的急性冠脉综合征患者,随机接受替格瑞洛或普拉格雷治疗。主要终点为1年死亡、心肌梗死或卒中复合终点,替格瑞洛组2012例中184例(9.3%)发生主要终点事件,普拉格雷组2006例中137例(6.9%)发生(HR 1.36;95%CI 1.09–1.70;P=0.006)。主要安全性终点大出血(BARC定义)替格瑞洛组5.4% vs 普拉格雷组4.8%(HR 1.12;95%CI 0.83–1.51;P=0.46),无显著差异。结论提示在该人群中普拉格雷较替格瑞洛降低缺血复合终点,出血风险无显著差异。
要点
- 计划行侵入性评估的急性冠脉综合征患者中,普拉格雷组1年死亡、心肌梗死或卒中复合终点6.9%,低于替格瑞洛组9.3%(HR 1.36;95%CI 1.09–1.70;P=0.006)。
- 主要终点各组分:死亡替格瑞洛组4.5% vs 普拉格雷组3.7%;心肌梗死4.8% vs 3.0%;卒中1.1% vs 1.0%。
- 大出血(BARC定义)替格瑞洛组5.4% vs 普拉格雷组4.8%(HR 1.12;95%CI 0.83–1.51;P=0.46),两组无显著差异。
- 明确或可能支架血栓替格瑞洛组1.3% vs 普拉格雷组1.0%;明确支架血栓1.1% vs 0.6%。
- 该试验为多中心、随机、开放标签设计,纳入计划行侵入性评估的急性冠脉综合征患者(伴或不伴ST段抬高)。
适用人群与场景
- 表现为急性冠脉综合征(伴或不伴ST段抬高)且计划行侵入性评估的患者。
研究设计与关键结果
- 多中心、随机、开放标签试验,共4018例患者随机分组:替格瑞洛组2012例,普拉格雷组2006例。
- 主要终点(1年死亡、心肌梗死或卒中复合终点):替格瑞洛组184/2012例(9.3%)vs 普拉格雷组137/2006例(6.9%),HR 1.36;95%CI 1.09–1.70;P=0.006。
- 主要终点组分:死亡替格瑞洛组4.5% vs 普拉格雷组3.7%;心肌梗死4.8% vs 3.0%;卒中1.1% vs 1.0%。
- 明确或可能支架血栓:替格瑞洛组1.3% vs 普拉格雷组1.0%;明确支架血栓:1.1% vs 0.6%。
- 主要安全性终点大出血(BARC定义):替格瑞洛组5.4% vs 普拉格雷组4.8%,HR 1.12;95%CI 0.83–1.51;P=0.46。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签试验(ISAR-REACT 5,NCT01944800)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在计划行侵入性评估的急性冠脉综合征患者中,作者结论为普拉格雷组死亡、心肌梗死或卒中发生率显著低于替格瑞洛组,大出血发生率两组无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain.
METHODS: In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year. A major secondary end point (the safety end point) was bleeding.
RESULTS: A total of 4018 patients underwent randomization. A primary end-point event occurred in 184 of 2012 patients (9.3%) in the ticagrelor group and in 137 of 2006 patients (6.9%) in the prasugrel group (hazard ratio, 1.36; 95% confidence interval [CI], 1.09 to 1.70; P = 0.006). The respective incidences of the individual components of the primary end point in the ticagrelor group and the prasugrel group were as follows: death, 4.5% and 3.7%; myocardial infarction, 4.8% and 3.0%; and stroke, 1.1% and 1.0%. Definite or probable stent thrombosis occurred in 1.3% of patients assigned to ticagrelor and 1.0% of patients assigned to prasugrel, and definite stent thrombosis occurred in 1.1% and 0.6%, respectively. Major bleeding (as defined by the Bleeding Academic Research Consortium scale) was observed in 5.4% of patients in the ticagrelor group and in 4.8% of patients in the prasugrel group (hazard ratio, 1.12; 95% CI, 0.83 to 1.51; P = 0.46).
CONCLUSIONS: Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups. (Funded by the German Center for Cardiovascular Research and Deutsches Herzzentrum München; ISAR-REACT 5 ClinicalTrials.gov number, NCT01944800.).
参考来源
- Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019. PMID: 31475799. doi:10.1056/NEJMoa1908973
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。